


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

INITIAL PRESENTATION

EVALUATION

FOLLOW-UP



¹ Fertility consideration (if clinically appropriate)

- Fertility decisions should be based on a patient's values, beliefs, morals, culture, and religious practices
 - Assessment and informative discussion of fertility desires should be conducted as part of treatment planning options that may impact fertility options
 - Fertility consult criteria:
 - Male greater or equal to 10 years old*
 - Premenopausal female greater or equal to 10 years old*
- * See MD Anderson Institutional policy CLN0547 for pediatric patients

² Assess need for:

- Referral to psychiatry or reproductive medicine psychologist for decision and emotional support
- Financial counseling regarding fertility preservation by fertility specialist

³ Fertility preservation options and length of time needed prior to starting cancer treatment that can impact fertility:

- Cryopreservation of sperm: 1-3 days needed
- Cryopreservation of embryos: 2-3 weeks needed
- Cryopreservation of oocyte: 2-3 weeks needed

Investigational fertility preservation options

- Ovarian suppression: up to 10 days needed
- Cryopreservation of ovarian or testicular tissue: variable, up to 3 days needed

⁴ Other options for fertility and parenthood

- Donor eggs, sperm, and embryos
- Adoption
- Gestational surrogacy

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

APPENDIX A: Sperm Banking and Fertility Consults

Consult for female fertility preservation or counseling for male fertility preservation at MD Anderson

- Go to Medications and Orders in OneConnect. Select Ambulatory Referral to Gynecologic Oncology Center and choose Onco Fertility button.
- For urgent consults, e-mail: Terri Woodard, MD at twoodard@mdanderson.org or Deborah Holman, RN, MSN, WHNP-BC at daholman@mdanderson.org

Sperm banking at Baylor College of Medicine Department of Urology

- Special Procedures Lab - upfront cost for analysis and one year storage \$550-\$650; without insurance infectious disease testing may be additional
- Phone number 713-798-4027
- Lab hours are Monday through Friday, 8 a.m. to 5 p.m.
- Patients need to have a cryopreservation referral form completed by their physician. To request a referral, call 713-798-4027.
- The form should be completed and faxed to Baylor requesting cryopreservation: fax number 713-798-6679
- Same day appointments are often available

Consult for pediatric fertility preservation or counseling at MD Anderson

- Go to Medications and Orders in OneConnect. Select Ambulatory Referral to Pediatrics and choose Onco Fertility button
- Call the Child and Adolescent Center Clinic at 713-792-6610
- For inpatient consults and urgent consults, page Donna A. Bell, MSN, RN, NP-C at 713-606-2256 or page John Andrew Livingston, MD at 713-606-1790

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

APPENDIX B: Patient Education and Websites

MDACC Patient Education (available through Patient Education Online)

- Fertility Options for Men and Women
- Fertility Options for Men who Need Cancer Treatment
- Fertility Options for Women Who Need Cancer Treatment
- Pregnancy and Cancer
- Pregnancy Test
- Preventing Pregnancy during Cancer Treatment
- Sexuality and Cancer
- Pathfinder--Fertility and Cancer: Provides a list of pamphlets, books and websites that are available to patients

Websites

www.ReproductiveFacts.org: The patient education website of the American Society for Reproductive Medicine. Under the publications tab, it includes printable informational booklets and fact sheets about a variety of issues including "Age and Fertility," Assisted Reproductive Technologies," "Cancer and Fertility Preservation," "Adoption," and "Third Party Reproduction."

www.livestrong.org: The national LIVESTRONG initiative dedicated to providing reproductive information, support and hope to cancer patients and survivors whose medical treatments present the risk of infertility. In addition to providing patient education and support, it also offers financial assistance for fertility and family building services.

Videos - Fertility Options for Female patients

The Female Reproductive System: <http://www3.mdanderson.org/streams/FullVideoPlayer.cfm?mediaID=297C3559-01F5-4F33-B2FC-8B046AEA7C85>

Cancer Treatment and Fertility: <http://www3.mdanderson.org/streams/FullVideoPlayer.cfm?mediaID=9B4732BF-6151-4053-A854-4B62F386B711>

Fertility Preservation Before Cancer Treatment: <http://www3.mdanderson.org/streams/FullVideoPlayer.cfm?mediaID=97EAAD28-32D9-4FA9-99C1-17C93DAAC0E7>

Family Planning After Cancer Treatment: <http://www3.mdanderson.org/streams/FullVideoPlayer.cfm?mediaID=0BE83F30-C1E7-48AF-8035-52EE778DDDF63>

Fertility Consultation: <http://www3.mdanderson.org/streams/FullVideoPlayer.cfm?mediaID=45EB224B-D593-4B52-8D1D-E9AF5130E97E>

Making Decisions: Patient Stories: <http://www3.mdanderson.org/streams/FullVideoPlayer.cfm?mediaID=98BC2659-724B-4BF8-9CC0-1CC3D1F0177F>

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- Aleem, I. S., Jalal, H., Aleem, I. S., Sheikh, A. A., & Bhandari, M. (2009). Clinical decision analysis: incorporating the evidence with patient preferences. *Patient Preference and Adherence*, 3, 21.
- American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. (2013). Mature oocyte cryopreservation: a guideline. *Fertility and Sterility*, 99(1):0015-0282.
- Anderson, R. A., & Wallace, W. H. B. (2013). Antimüllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. *Fertility and Sterility*, 99(6), 1469-1475.
- Bedoschi, G., & Oktay, K. (2013). Current approach to fertility preservation by embryo cryopreservation. *Fertility and Sterility*, 99(6), 1496-1502.
- Cakmak, H., & Rosen, M. P. (2013). Ovarian stimulation in cancer patients. *Fertility and Sterility*, 99(6), 1476-1484.
- Campo-Engelstein, L. (2010). Consistency in insurance coverage for iatrogenic conditions resulting from cancer treatment including fertility preservation. *Journal of Clinical Oncology*, 28(8), 1284-1286.
- Chung, K., Donnez, J., Ginsburg, E., & Meirou, D. (2013). Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. *Fertility and Sterility*, 99(6), 1534-1542.
- Cobo, A., Garcia-Velasco, J. A., Domingo, J., Remohí, J., & Pellicer, A. (2013). Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients? *Fertility and Sterility*, 99(6), 1485-1495.
- Donnez, J. (2013). Introduction: fertility preservation, from cancer to benign disease to social reasons: the challenge of the present decade. *Fertility and Sterility*, 99(6), 1467-1468.
- Georgescu, E. S., Goldberg, J. M., du Plessis, S. S., & Agarwal, A. (2008). Present and future fertility preservation strategies for female cancer patients. *Obstetrical & Gynecological Survey*, 63(11), 725-732.
- Holoch, P., & Wald, M. (2011). Current options for preservation of fertility in the male. *Fertility and Sterility*, 96(2), 286-290.
- Kidger, J., Murdoch, J., Donovan, J. L., & Blazeby, J. M. (2009). Clinical decision-making in a multidisciplinary gynaecological cancer team: a qualitative study. *BJOG: An International Journal of Obstetrics & Gynaecology*, 116(4), 511-517.

Continued on Next Page

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS - continued

- Loren, A. W., Mangu, P. B., Beck, L. N., Brennan, L., Magdalinski, A. J., Partridge, A. H., ... & Oktay, K. (2013). Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *Journal of Clinical Oncology*, 31(19), 2500-2510.
- Marhhom, E., & Cohen, I. (2007). Fertility preservation options for women with malignancies. *Obstetrical & Gynecological Survey*, 62(1), 58-72.
- National Comprehensive Cancer Network. Clinical Practice Guidelines for Adolescents and Young Adults (AYA) Oncology (Version 1.2017). <https://www.nccn.org/patients/guidelines/aya/files/assets/basic-html/page-1.html#>. Accessed May 30, 2018
- Oktay, K., Harvey, B. E., Partridge, A. H., Quinn, G. P., Reinecke, J., Taylor, H. S., ... & Loren, A. W (2018) Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. *Journal of Clinical Oncology*, 36(19), 1994-2001.
- Sainio, C., Eriksson, E., & Lauri, S. (2001). Patient participation in decision making about care: The cancer patient's point of view. *Cancer Nursing*, 24(3), 172-179.
- Smits, J., Dolmans, M. M., Donnez, J., Fortune, J. E., Hovatta, O., Jewgenow, K., ... & Telfer, E. E. (2010). Current achievements and future research directions in ovarian tissue culture, in vitro follicle development and transplantation: implications for fertility preservation. *Human Reproduction Update*, 16(4), 395-414.
- Tempest, H. G., Ko, E., Chan, P., Robaire, B., Rademaker, A., & Martin, R. H. (2007). Sperm aneuploidy frequencies analysed before and after chemotherapy in testicular cancer and Hodgkin's lymphoma patients. *Human Reproduction*, 23(2), 251-258.
- UTMDACC Institutional Policy #CLN0547- Informed Consent Policy.
- West, E. R., Zelinski, M. B., Kondapalli, L. A., Gracia, C., Chang, J., Coutifaris, C., ... & Woodruff, T. K. (2009). Preserving female fertility following cancer treatment: current options and future possibilities. *Pediatric Blood & Cancer*, 53(2), 289-295.

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

DEVELOPMENT CREDITS

This practice consensus statement is based on majority opinion of the Fertility workgroup at the University of Texas MD Anderson Cancer Center for the patient population. These experts included:

John Araujo, MD (Genitourinary Medical Oncology)
Donna Bell RN, MSN, NP-C (Pediatrics)
Charles Cowles, MD (Anesthesiology and PeriOper Medicine)
Olga Fleckenstein[♦]
Colleen Gallagher, PhD (Critical Care and Respiratory Care)
Deborah A Holman, RN, MSN, WHNP-BC (Gynecologic Oncology & Reproductive Medicine)
Mary Hughes RN, MSN, APN (Psychiatry)
Elizabeth Keeler, MD (Gynecologic Oncology & Reproductive Medicine)
Jennifer Litton, MD (Breast Medical Oncology)[‡]
John Andrew Livingston, MD (Sarcoma Medical Oncology)
Jeffrey A. Lockett, BSN, RN[♦]
Christopher Logothetis, MD (Genitourinary Medical Oncology)
Andrea Milbourne, MD (Gynecologic Oncology & Reproductive Medicine)
Pamela Soliman, MD (Gynecologic Oncology & Reproductive Medicine)
Terri Lynn Woodard, MD (Gynecologic Oncology & Reproductive Medicine)[‡]

[‡]Core Development Team

[♦]Clinical Effectiveness Development Team